Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C → A polymorphism in intron 1 of the CYP1A2 gene: Effect of grapefruit juice and low-dose fluvoxamine

Journal of Clinical Psychopharmacology

Volumn 21, Issue 6, 2001, Pages 603-607

  Özdemir, Vural ^a,b   Kalow, Werner ^a   Okey, Allan B ^a   Lam, Maria S M ^a   Albers, Lawrence J ^c   Reist, Christopher ^c   Fourie, Jeanne ^a   Posner, Paul ^b   Collins, Evan J ^b   Roy, Rochelle ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; CLOZAPINE; CYTOCHROME P450 1A2; FLUVOXAMINE; LOXAPINE; NORCLOZAPINE; PERPHENAZINE; RISPERIDONE; TETRACYCLINE; TRIFLUOPERAZINE;

ADULT; ARTICLE; CASE REPORT; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; GRAPE; HUMAN; INTRON; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; STEADY STATE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BEVERAGES; CITRUS; CLOZAPINE; CYTOCHROME P-450 CYP1A2; FLUVOXAMINE; HUMANS; INTRONS; MALE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 18244426328     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200112000-00011     Document Type: Article

References (31)

1. Clozapine. A novel antipsychotic agent
2. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic
3. Treatment of schizophrenia and spectrum disorders: Pharmacotherapy, psychosocial treatments, and neurotransmitter interactions
4. Pharmacologic treatment of schizophrenia
5. The evolution of treatment-resistance: Biological implications
6. Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine
7. Neurotransmitter-related genes and antipsychotic response: Pharmacogenetics meets psychiatric treatment
8. Pharmacogenetic prediction of clozapine response
9. Genetics and etiology of schizophrenia and bipolar disorder
10. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test
11. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia
12. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine
13. Will routine therapeutic drug monitoring have a place in clozapine therapy?
14. Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
15. Caffeine as a metabolic probe: Exploration of the enzyme-inducing effects of cigarette smoking
16. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
17. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
18. The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography
19. Very high cytochrome P4501A2 activity and nonresponse to clozapine
20. Disposition of clozapine in man: Lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms
21. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes
22. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients
23. Phenacetin O-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine
24. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants
25. Absence of interaction between erythromycin and a single dose of clozapine
26. The effect of nefazodone on clozapine plasma concentrations
27. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole
28. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia
29. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: Two case reports